Patents by Inventor Ann M. English

Ann M. English has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAPID IDENTIFICATION AND SEQUENCE ANALYSIS OF INTACT PROTEINS IN COMPLEX MIXTURES
    Publication number: 20230178350
    Abstract: The present disclosure relates to novel and improved methods of analyzing proteins, peptides and polypeptides by mass spectrometry using ion-ion reactions. More specifically the disclosure relates to improved methods for implementing the m/z selective arresting of ion-ion reactions within the ion-ion reaction cell of a mass spectrometer system during a period where ion-ion reactions are performed.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 8, 2023
    Inventors: Donald F. HUNT, Ann M. ENGLISH, Scott A. UGRIN, Dina L. BAI, Jeffrey SHABANOWITZ, John Edward Philip SYKA
  • Rapid identification and sequence analysis of intact proteins in complex mixtures
    Patent number: 11538675
    Abstract: The present disclosure relates to novel and improved methods of analyzing proteins, peptides and polypeptides by mass spectrometry using ion-ion reactions. More specifically the disclosure relates to improved methods for implementing the m/z selective arresting of ion-ion reactions within the ion-ion reaction cell of a mass spectrometer system during a period where ion-ion reactions are performed.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: December 27, 2022
    Assignees: University of Virginia Patent Foundation, Thermo Finnigan LLC
    Inventors: Donald F. Hunt, Ann M. English, Scott A. Ugrin, Dina L. Bai, Jeffrey Shabanowitz, John Edward Philip Syka
  • CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
    Publication number: 20220041655
    Abstract: A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and el B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
    Type: Application
    Filed: February 18, 2021
    Publication date: February 10, 2022
    Inventors: Donald F. HUNT, Jeffrey SHABANOWITZ, Jennifer COTTINE HITCHCOCK, Ann M. ENGLISH, Andrew NORRIS, Victor H. ENGELHARD, Mark COBBOLD, Kara L. CUMMINGS, Angela L. AMBAKHUTWALA, Rebecca C. OBENG, Jie QIAN
  • RAPID IDENTIFICATION AND SEQUENCE ANALYSIS OF INTACT PROTEINS IN COMPLEX MIXTURES
    Publication number: 20200312643
    Abstract: The present disclosure relates to novel and improved methods of analyzing proteins, peptides and polypeptides by mass spectrometry using ion-ion reactions. More specifically the disclosure relates to improved methods for implementing the m/z selective arresting of ion-ion reactions within the ion-ion reaction cell of a mass spectrometer system during a period where ion-ion reactions are performed.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 1, 2020
    Inventors: Donald F. HUNT, Ann M. ENGLISH, Scott A. URGIN, Dina L. BAI, Jeffrey SHABANOWITZ, John Edward Philip SYKA
  • CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
    Publication number: 20180066017
    Abstract: A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
    Type: Application
    Filed: April 10, 2017
    Publication date: March 8, 2018
    Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Jennifer Cottine, Ann M. English, Andrew Norris, Victor H. Engelhard, Mark Cobbold, Kara L. Cummings, Angela Zarling, Rebecca C. Obeng, Jie Qian
  • CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
    Publication number: 20130259883
    Abstract: A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
    Type: Application
    Filed: May 24, 2011
    Publication date: October 3, 2013
    Applicant: PHOSIMMUNE, INC.
    Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Jennifer Cottine, Ann M. English, Andrew Norris, Victor H. Engelhard, Mark Cobbold, Kara L. Cummings, Angela Zarling, Rebecca C. Obeng, Jie Qian